Top image

Julius Kim & team: Systematic effects of Gioblastoma multiforme (GBM) and GBM-released extracellular vesicles on immune suppression

RESEARCH TYPE
T1,T2
PROGRAM
Flagship 2 Pilot and Seed
TAGS
    Dendritic cell
STATUS
In Progress

Despite recent improvements in cancer therapies, the median survival for patients with brain tumours is only 15 months. We need to urgently develop better treatment options. Anti-tumour vaccination has promise as a therapy and can be rapidly developed for clinical use. However, vaccines for brain tumours have only demonstrated limited efficacy to date. One of the main reasons is brain tumour induced local and systemic immune dysfunction. In this project we seek to understand and reduce the immune dysfunction caused by brain tumours. This will allow us to improve on the next generation of brain tumour vaccines and improve clinical outcomes in patients.

Pilot and Seed Funding Awarded:

  • CIA: Julius Kim (Georgina Clark from December 2018)
  • Member Group: ANZAC Research Institute
  • Year and Duration: 2018 for 12 months
  • Amount: $50,000

5 Minutes with Julius Kim

What was the catalyst to you researching this topic right now?

I moved Australia and started to pursue my research in Dendritic Cell Research (DCR), ANZAC Research Institute in 2017. As a young researcher and new in Australia, Sydney Catalyst was the best organisation to meet/interact with people. Getting support from the catalyst for this research will help me to build up preliminary data for a bigger grant such as a NHMRC project grant. Eventually, this support from the Sydney Catalyst will be the seed for my research to transit into clinic. 

Why will this investigation be important in the field of translational research?

Our proposed research is highly necessary for GBM immunotherapy since GBM facilitates local and systemic immunosuppression. We will be able to dissect effect of GBM and GBM released EV on systemic immunity and find out an optimal way to revert this effect, re-activating immune system to be against GBM. Therefore, information acquired from our proposed research will give a mechanistic guidance for immunotherapy against GBM in clinics as systemic immunosuppression has to be overcome to achieve clinical efficacy.

This project involves:

Dendritic Cell Research Group - Dr Julius Kim, Associate Professor Georgina Clark and Dr Ben Kong.

Neuropathy Department at RPA - Associate Professor Michael Buckland and Dr Kimberly Kaufman.

If you could be anywhere in the world right now, where would you be?

Sydney, Australia! The best place to pursue my research!!

You might also be interested in...

  • T1
    Ashleigh Morgan: From mice to men: biomarker driven classification of pancreatic cancer to define novel targetable molecular subtypes
    Due to the extremely poor prognosis of pancreatic cancer, and current therapies only being marginally effective, there is an urgent need to develop novel therapeutic strategies. This study aim...
      Biomarkers
      Personalised medicine
      New therapies and diagnostics
  • T1
    Ben Kong: Towards a therapeutic vaccination for glioblastoma multiforme
    The ultimate objective of Ben's research is to create an effective dendritic cell based vaccine for glioblastoma multiforme by exploiting knowledge of DC biology to find the optimum combinatio...
      Dendritic cell
      Immunotherapy
  • T1
    CINSW RIGs and REGs
    The CINSW Research Equipment and Infrastructure Grants Program is directed to providing substantial funding for key research platforms, core equipment and capacities to enhance the cancer rese...
      Research Equipment
      Research Infrastructure
      CINSW
  • T1
    Claire Vennin: Preclinical targeting of the extracellular matrix to improve chemotherapy and reduce metastasis in patient-stratified models of pancreatic cancer using innovative imaging technologies
    A major challenge in cancer research is to understand and counteract mechanisms of drug resistance. This project will (1) shed light on the role of the ECM in chemoresistance and (2) guide the...
      Biomarkers
      New therapies and diagnostics
  • T1
    David Croucher: Mapping and manipulating therapeutically induced JNK network architecture to tackle breast cancer chemoresistance
    The current generation of cancer therapies mostly target components of signalling pathways, being either small molecule inhibitors or monoclonal antibodies to cell surface receptors. It is fas...
      Breast Cancer
      Chemo resistance
  • T1,T2
    David Thomas: Molecular Screening and Therapeutics Program (MOST)
    The rapid advance in genomic technologies presents the unprecedented opportunity to molecularly phenotype cancers and link genetic information to therapeutic opportunities for individual patie...
      Genetics/genomics
      Personalised medicine
      New therapies and diagnostics
  • T1
    Fast Linear Laser Scanning Technology: The ZEISS LSM 800 Confocal Microscope for the Open Access, Bosch Institute Advanced Microscopy Facility
    Funding was awarded for revolutionary technology, the ZEISS LSM 800 confocal microscope with Airyscan, for the Open-Access, Multi-User Bosch Institute Advanced Microscopy Facility (AMF) at the Uni...
      CINSW Research Equipment Grant
  • T1
    Hayley Suen & team: Restoring the Function of Clonal Cytotoxic T cells in Multiple Myeloma to Develop Novel Therapies and Define the Antigenic Landscape
    Multiple myeloma is an incurable disease so new treatments are required to provide a cure for patients. An attractive form of treatment is the use of a patient's own T cells to fight their can...
      Immunotherapy
      New therapies and diagnostics
      Myeloma
  • T1
    Helen McGuire: Development of a novel test to predict clinical response to checkpoint therapy in lung cancer and mesothelioma
    Immune checkpoint inhibitor therapy has provided new hope to cancer patients whose tumours have resisted conventional therapy. One of the most recent success stories has been effective treatmen...
      Immunotherapy
      New therapies and diagnostics
      Lung cancer
      Mesothelioma
  • T1
    Jeff Holst & team: Targeting glutamine metabolism to starve triple-negative breast cancer
    Jeff's team are studying nutrient pumps that bring the amino acid glutamine into cancer cells. They have discovered that these pumps are increased in triple-negative breast cancer, a subset tha...
      Cancer metabolism
      New therapies and diagnostics
      Breast Cancer
  • T2
    John Simes: MDT scoping project
    The aim of this research was to describe the multi-disciplinary teams (MDTs) in our consortium and to share findings with survey participants to provide them an opportunity to learn more abou...
      MDT
  • T2
    Jolyn Hersch: Supporting informed choice for management of screen-detected Ductal Carcinoma in Situ (DCIS) among older women (70 years and over)
    Breast screening often finds ductal carcinoma in situ (DCIS) - cell changes which may or may not become cancer later on. Treatments for DCIS (surgery, radiation and drugs) have harmful side ef...
      Psychosocial
      Breast Cancer
  • T2
    Kate White & team: The financial impact of cancer treatment on Australian patients and families
    It is recognised that individuals and their families experience financial costs associated with the diagnosis of cancer and subsequent treatment.  Little attention has been paid to identi...
      Psychosocial
      Cancer costs
  • T1
    LC-PLAT - Lung Cancer Cohort - a Platform to Study Serial Biospecimens and Matched Clinical Data
    The project aimed to optimise a platform for the collection of serial lung cancer tissue and blood biospecimens for research during routine clinical practice. Prospective biobanking and collection...
      Lung cancer
      Biobanking
  • T1
    Lorraine Chantrill and team: IMPACT Trial
    Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) aimed to improve outcomes for patients with advanced pancreas cancer by using molecular analysis of tumor tissue to guide treatment ...
      Personalised medicine
      Clinical Trials
      Pancreatic cancer
      Treatment
  • T1
    Magdalena Budzinska: Discovering Novel Non-Invasive Diagnostic and Prognostic Markers in Hepatocellular Carcinoma
    Magdalena's research addresses the urgent need in HCC management for markers that predict HCC propensity and behaviour. It has the potential to be translated into clinical practice at the level...
      Biomarkers
      New therapies and diagnostics
  • T1
    Mark Larance: Nutrient Deprivation and the Protective Proteome for the Prevention of Disease
    Cancer is a major cause of illness and death in Australia. Key risk factors for colorectal cancer and many other cancer types are poor diet, obesity and age. In animals, short periods of nutrient ...
      Cancer metabolism
      Colorectal cancer
      Proteomics
  • T2
    Nicole Rankin and Team: Sydney Catalyst Member Experience Survey
    The aim of this research was to qualitatively explore the experiences of members of Sydney Catalyst to identify members' understanding and perceptions of translational research, benefits of me...
      Member Experience
  • T1,T2
    Peter Luk & team: Understanding the Body's Response to Cancer Invasion and Progression
      Cutaneous squamous cell carcinoma (cSCC; skin cancer) is the most common human cancer with the potential to spread to other parts of the body. Australia has the highest rate of cSCC i...
      Head and Neck Cancer
  • T1
    Philip Hogg: ACRF Centenary Cancer Research Centre
    The goal of the ACRF Centenary Cancer Research Centre is to understand the link between diet, metabolism and tumour initiation and development at a molecular level, and to design new therapies usi...
      Cancer metabolism
      New therapies and diagnostics
  • T1,T2
    Philip Hogg: Measure of thrombotic risk in cancer patients
    Thrombotic events are a major cause of death in cancer patients and are associated with worsened short‐term and long‐term survival. Prof Hogg and his team developed a new diagnostic test for ...
      Thrombosis
  • T1
    Roger Bourne & team: Gold-standard assessment of prostate cancer MRI accuracy
    A recent health economics analysis identified doctors' lack of confidence in prostate MRI as a major inhibitor to increased choice of active surveillance for low risk prostate cancer. Furthermore,...
      Imaging
      Urogenital
      Prostate
      MRI
  • T1
    Sarah Sutherland: Novel targets for a new generation of therapeutic cancer vaccines
    DC vaccines are well tolerated and can induce an anti- tumour immune response. Current vaccine strategies use in vitro generated "DC" which are loaded with antigen, stimulated and transfused back ...
      Dendritic cell
      Immunotherapy
      Urogenital
  • T1
    Sonia Yip: Biobanking - Patient and healthcare Professional Attitudes and Experiences of universal consent (B-PPAE)
    The Biobanking Qualitative Evaluation Project was initially developed to explore patient and health professional views of universal consent for biobanking procedures. It was later expanded to ...
      Lung cancer
      Biobanking
      Consent
  • T1,T2,T3
    Sydney Catalyst Scholarships Awarded pre July 2016
    We aim to encourage training and development of outstanding researchers and clinicians from within Sydney Catalyst units, who have the potential to develop highly significant ca...
      Scholarships
  • T1,T2,T3
    Sydney Catalyst: Embedding Research in Cancer Healthcare (EnRICH)
      The EnRICH program is a prospective clinical cohort of 1000 patients with lung cancer, which aims to better define, treat and care for patients in Sydney Catalyst member hospitals...
      Epidemiology and health services research
      Implementation research
      Knowledge translation
      Lung cancer
  • T1
    The Next Wave of Cancer Genomics: Resolving Complex Structural Variants and Tumour Heterogeneity with Linked Short-Read
    Large genomic structural rearrangements are just important as short mutations in cancer pathogenesis. However, these critical events are often missed by conventional sequencing technologies. The f...
      CINSW Research Equipment Grant
  • T1
    Thomas Cox: Biomechanical priming of organotropism in metastasising breast cancer cells
    Breast cancer is the most common cancer in women worldwide. It is estimated that more than 1.7 million new cases of breast cancer occurred among women worldwide in 2012. We already know that ti...
      Breast Cancer
      Tissue stiffness
      Metastasis
  • T1
    Thomas Johnson: YB-1: A central player in the carcinogenesis and malignant behaviour of malignant pleural mesothelioma
    Malignant pleural mesothelioma (MPM) is an aggressive, asbestos-induced malignancy that responds poorly to treatment. The combination of cisplatin and pemetrexed, which is the current standard...
      Biomarkers
      Mesothelioma